We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+0.7%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.09B
AUM Growth
+$50.8M
Cap. Flow
+$91.6M
Cap. Flow %
8.41%
Top 10 Hldgs %
59.85%
Holding
90
New
23
Increased
22
Reduced
6
Closed
21

Top Buys

Rank Stock Value
1
NXTC icon
NextCure
NXTC
+$43.7M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$34.6M
3
PTCT icon
PTC Therapeutics
PTCT
+$14.6M
4
ASND icon
Ascendis Pharma A/S
ASND
+$12.1M
5
XLRN
Acceleron Pharma
XLRN
+$9.98M

Top Sells

Rank Stock Value
1
CHRS icon
Coherus Oncology
CHRS
+$13.5M
2
AZN icon
AstraZeneca
AZN
+$10.6M
3
ANAB icon
AnaptysBio
ANAB
+$7.16M
4
XNCR icon
Xencor
XNCR
+$6.52M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$6.43M

Sector Composition

Rank Sector Weight
1 Healthcare 88.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
76
PUT
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
– –
-20,000
Closed -$2.35M
INSM icon
77
Insmed
INSM
$23.2B
– –
-140,057
Closed -$4.07M
OEF icon
78
PUT
iShares S&P 100 ETF
OEF
$19.8B
– –
-242,000
Closed -$27.1M
PBYI icon
79
CALL
Puma Biotechnology
PBYI
$406M
– –
-93,800
Closed -$3.64M
SVRA icon
80
Savara
SVRA
$1.13B
– –
-766,672
Closed -$5.65M
XNCR icon
81
Xencor
XNCR
$1.44B
– –
-209,907
Closed -$6.52M
DCPH
82
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-214,604
Closed -$5.02M
IMGN
83
CALL
DELISTED
Immunogen Inc
IMGN
– –
-150,000
Closed -$406K
ICPT
84
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-44,918
Closed -$5.02M
HSTO
85
CALL
DELISTED
Histogen Inc. Common Stock
HSTO
– –
-750
Closed -$162K
GWPH
86
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-20,000
Closed -$3.37M
PTLA
87
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-30,000
Closed -$1.04M
BHVN
88
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-124,952
Closed -$6.43M
1 2 3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2019 Portfolio in Review

As of Q2 2019, Sofinnova Investments held 90 positions worth $1.09B, up 4.9% from $1.04B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sofinnova Investments deployed $91.6M of net new capital in Q2 2019, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was NextCure: 210,155 shares worth $37.8M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 84% a quarter earlier.

On the sell side, the largest reduction was Coherus Oncology, an estimated $13.5M trimmed.

  • Sofinnova Investments's largest Q2 2019 buy was NextCure: 210,155 shares worth $37.8M.
  • Sofinnova Investments added most to Ascendis Pharma A/S in Q2 2019, an estimated $12.1M increase.
  • Sofinnova Investments's biggest Q2 2019 reduction was Coherus Oncology, cutting an estimated $13.5M.
  • Sofinnova Investments fully exited AstraZeneca in Q2 2019, selling an estimated $10.6M.
  • Sofinnova Investments's ten largest holdings make up 60% of its $1.09B portfolio in Q2 2019.
  • Sofinnova Investments opened 23 new positions and closed 21 in Q2 2019.
  • Sofinnova Investments's portfolio value rose 4.9% quarter-over-quarter to $1.09B.

Based on Sofinnova Investments's 13F filing for Q2 2019, filed 13 Aug 2019.